By Fineline Cube Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and DeepMed Technology (Suzhou) Co., Ltd. have officially signed a strategic cooperation agreement on AI‑driven drug research and development.
Deal Milestone
| Item | Detail |
|---|---|
| Party A | Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) — leading integrated new drug R&D complex in China |
| Party B | DeepMed Technology (Suzhou) Co., Ltd. — AI‑driven application and translation platform empowering biopharmaceutical innovation |
| Agreement Type | Strategic cooperation agreement on AI‑driven drug R&D |
| Core Model | Closed‑loop system combining “AI in silico intelligent design + traditional wet‑lab validation and translation” |
| Scope | Dedicated therapeutic areas; long‑term collaborative development for specific targets and projects |
| Strategic Goal | Build a differentiated pipeline of innovative drug candidates |
Partnership Structure — Closed‑Loop R&D System
Within dedicated therapeutic areas, the two parties will jointly establish a closed‑loop new drug R&D system:
| Component | Role |
|---|---|
| AI in silico intelligent design (DeepMed) | Computational target identification, molecular design, and candidate optimization |
| Wet‑lab validation and translation (Sun‑Novo) | Experimental confirmation and translational development within an integrated R&D complex |
| Long‑term collaboration | Joint development for specific targets and projects, strategically building a differentiated pipeline |
Key Technology Areas
- Nano‑targeted antibody discovery and engineering for delivery systems
- Therapeutic or targeted cyclic peptide design
- RNA‑targeted small‑molecule compound discovery
- Multi‑target small‑molecule drug discovery
Market Impact & Outlook
- AI Drug Discovery Goes Closed‑Loop: By pairing DeepMed’s in silico design engine with Sun‑Novo’s wet‑lab validation infrastructure, the partnership addresses a core bottleneck in AI‑driven discovery — the iterative feedback cycle between computational prediction and experimental confirmation.
- Modality Breadth: The four technology areas span the industry’s fastest‑growing modalities — antibodies, cyclic peptides, RNA‑targeted small molecules, and multi‑target agents — positioning the pipeline for differentiation beyond conventional single‑target small molecules.
- Listed‑Company Exposure: For Sun‑Novo (SHA: 688621), the agreement accelerates pipeline diversification through an asset‑light AI partnership rather than wholly in‑house discovery spending.
- Platform Validation for DeepMed: A long‑term strategic tie with an established Chinese R&D complex extends DeepMed’s translation track record across multiple modalities and therapeutic areas.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding AI‑driven discovery programs, pipeline development, and collaboration outcomes. Actual results may differ due to risks including research feasibility, preclinical and clinical outcomes, regulatory timelines, and competitive dynamics.-Fineline Info & Tech